Weekly Briefing

Men's health news, explained

New briefings every Monday

Rules on testosterone, telehealth prescribing, compounded drugs, and health advertising change often, and those changes affect what treatment you can get and how. Each week we scan the agencies and the news, then explain what changed and what it means for you.

Latest briefing · September 25, 2026

FDA warns Empower Pharmacy, DEA telehealth deadline nears, testosterone labels change

The FDA warned Empower Pharmacy that two of its GLP-1 combination products appear to be copies of approved drugs.
Rules allowing testosterone to be prescribed by telehealth without an in-person visit expire December 31, and a permanent DEA rule is under final review.
FDA has asked drugmakers to remove the "age-related hypogonadism" limitation from testosterone labels.

Read the briefing →

All briefings

Sep 25, 2026Launch edition: Empower warning letter, DEA telehealth deadline, testosterone label changesPlus the FTC's Hims & Hers lawsuit, telehealth privacy, and Medicare telehealth through 2027.

What we track

FDADrugs & safetyApprovals, label changes, safety alerts, and warning letters on testosterone, GLP-1s, ED and hair-loss drugs, compounding, and tainted supplements.

DEAControlled substancesTelemedicine prescribing rules and scheduling decisions that affect testosterone and other controlled medications.

FTCAdvertising & privacyEnforcement against misleading health claims, subscription traps, and health-data sharing by telehealth companies and supplement sellers.

TelehealthAccess & coverageMedicare and federal telehealth policy, and significant state laws on online prescribing.

In the newsResearch & reportingMajor studies, investigations, and news coverage on the topics this site covers.

How we put it together

Primary sources first. Every item links to the agency announcement, court filing, or original reporting, or to a reputable summary when the original isn't publicly accessible.
Only what matters to readers. We skip industry business news unless it changes what treatment you can get, what it costs, or how safe it is.
Allegations are labeled as allegations. Lawsuits and warning letters describe what regulators claim, not proven findings.
No affiliate interest. Coverage of a company, including providers in our directory, is never paid or influenced by them.

Briefings are compiled with the help of automated research tools each week and written to the same editorial standards as the rest of the site.

Briefings summarize publicly reported news and government actions for general education. They are not medical or legal advice. Always confirm details with the original sources and talk to a licensed physician before changing any treatment.